CLAIMS

1. Use of nerve growth factor (NGF) in the preparation of a pharmaceutical composition for treating neuropathic corneal pain (NCP) in a subject in need thereof.

2. The use according to claim 1, wherein said NGF is rhNGF.

3. The use according to claim 1 or 2, wherein said subject is a patient suffering from NCP with a response to a topical anesthetic, preferably proparacaine, and/or who have mild inflammation.

4. The use according to any one of claims 1 to 3, wherein the subject has a Dendritiform Cell Density (cells/mm^2) lower than 75, preferably lower than 70.

5. The use according to any one of claims 1 to 4, wherein the subject is a patient suffering from peripheral or mixed NCP.

6. The use according to any one of claims 1 to 5, wherein the subject is a patient that does not suffer from dry eye disease (DED) and/or from neurotrophic keratitis (NK).

7. The use according to any one of claims 1 to 6, wherein NGF is to be administered topically to an ocular surface of the subject, in the form of a pharmaceutical composition for ophthalmic use.

8. The use according to claim 7, wherein NGF is present in the pharmaceutical composition at concentrations ranging from about 0.0001% to about 0.5% w/v, more preferably from about 0.001% to about 0.1% w/v, most preferably of about 0.002% w/v.

9. The use according to any one of claims 1 to 8, wherein said NGF is to be administered between 3 and 6 times a day for a period between 4 and 12 weeks.